Drug Search Results
More Filters [+]

GX-G6

Alternative Names: gx-g6, gxg6, gx g6
Latest Update: 2021-07-20
Latest Update Note: News Article

Product Description

GX-G6 is long-acting GLP-1 based on Genexines proprietary hyFc Platform technology for type 2 diabetes (T2D) targeting both weekly and twice-monthly regimen compared to conventional daily therapeutics.

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Genexine
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GX-G6

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: General Diabetes|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GX-G6-002

P2

Unknown status

Type 2 Diabetes

2022-06-01

23%

GX-G6_HV1

P1

Completed

Healthy Volunteers|General Diabetes

2018-06-06

28%

Recent News Events